BioSpace News Archive

Forma Therapeutics Announces Appointment of Acclaimed Global Sickle Cell Disease Leader Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Chief Patient Officer.

Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT) — the global leader in medical technology — announced it has received a Health Canada licence for the GI Genius™ intelligent endoscopy module.

Palatin Technologies, Inc. today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for application No.: 16/927,347.

T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, announced that biotech industry veteran Laura Brege has been appointed to the company’s Board of Directors.

Hepion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for the Company’s lead drug candidate, CRV431, for the treatment of NASH.

Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Company’s Board of Directors approved the grant of stock options to purchase an aggregate of 180,000 shares of the Company’s common stock to two new employees on the date that each employee commences service with the Company.

Organovo Holdings, Inc., provided a business overview and progress update, and announced it is on track to establish its first models of inflammatory bowel disease in 2022 using its 3D bioprinting and other 3D tissue technologies.

GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced it will commence preparation for clinical trials of its rapid SARS-CoV-2 Antibody test following the recent successful completion of a clinical validation study.

aTyr Pharma, Inc. (Nasdaq: LIFE), and FUJIFILM Diosynth Biotechnologies, today announced a manufacturing agreement for ATYR1923, aTyr Pharma’s lead therapeutic candidate that is currently in clinical development for pulmonary sarcoidosis, a major form of interstitial lung disease (ILD).

Sciwind Biosciences Co., Ltd. announced that it has signed a global, exclusive license agreement with Sanofi to develop and commercialize Sanofi’s long-lasting glucose-dependent insulinotropic polypeptide receptor agonists, with the lead candidate currently under preclinical development.